Candesartan cilexetil: A review of its preclinical pharmacology

Journal of Human Hypertension

Volumn 11, Issue SUPPL. 2, 1997, Pages

  Nishikawa, K ^a   Naka, T ^a   Chatani, F ^a   Yoshimura, Y ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Animal studies; Candesartan cilexetil; In vitro studies; Pharmacology; Review; Rodent models

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II ANTAGONIST; CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL;

ARTICLE; BRAIN PROTECTION; DOSE RESPONSE; DRUG POTENCY; DRUG RECEPTOR BINDING; GASTROINTESTINAL ABSORPTION; HEART HYPERTROPHY; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; ORAL DRUG ADMINISTRATION; RENOVASCULAR HYPERTENSION; STROKE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; HEMODYNAMIC PROCESSES; HUMANS; RECEPTORS, ANGIOTENSIN; TETRAZOLES;

EID: 0030679672     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Kubo K et al. Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of benzimidazolecarboxylic acids. J Med Chem 1993; 36: 2182-2195.
2. Kubo K et al. Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids. J Med Chem 1993; 36: 2343-2349.
3. Noda M et al. Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist. Biochem Pharmacol 1993; 46: 311-318.
4. Shibouta Y et al. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole- 7-carboxylic acid (CV-11974) and its prodrug, (±)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl] methyl]-1H-benzimidazole-7-carboxylate (TCV-116). J Pharmacol Exp Ther 1993; 266: 114-120.
5. 1 receptor. Eur J Pharmacol 1997; 319: 137-146.
6. Itoh K, Shiomi M, Kitoh G. Effects of the non-peptide angiotensin II receptor antagonist, TCV-116, on systemic and renal hemodynamics in dogs with renal hypertension. Hypertens Res 1995; 18: 69-75.
7. 1) receptor antagonist candesartan cilexetil (TCV-116) and the angiotensin converting enzyme inhibitor enalapril in rats. Hypertens Res 1996; 19: 75-81.
8. 1)-receptor antagonist, (±)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl) biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116), in various hypertensive rats. J Pharmacol Exp Ther 1994; 268: 1540-1547.
9. Nishikawa K et al. Pharmacological profile of a novel nonpeptide angiotensin II subtype 1 receptor antagonist, TCV-116. Blood Press 1994; 3 (Suppl 5): 7-14.
10. Wada T et al. Combined effects of the angiotensin II antagonist candesartan cilexetil (TCV-116) and other classes of antihypertensive drugs in spontaneously hypertensive rats. Hypertens Res 1996; 19: 247-254.
11. 1 receptor antagonist, in conscious spontaneously hypertensive rats. Jpn J Pharmacol 1997; 73: 185-190.
12. Ojima M et al. Attenuation of neurotransmission by angiotensin II receptor antagonist, candesartan (CV-11974), in spontaneously hypertensive rats. Jpn Pharmacol Ther 1996; 24: 1433-1438.
13. Wada T et al. Effect of an angiotensin II receptor antagonist, CV-11974, and its prodrug, TCV-116, on production of aldosterone. Eur J Pharmacol 1994; 253: 27-34.
14. Inada Y et al. Protective effects of candesartan cilexetil (TCV-116) on stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats. Clin Exp Hypertens 1997, In press
15. Kim S et al. Contribution of renal angiotensin II type 1 receptor to gene expressions in hypertension-induced renal injury. Kidney Intern 1994; 46: 1346-1358.
16. 1 and extracellular matrix in cardiac and vascular tissues of hypertensive rats, J Pharmacol Exp Ther 1995; 273: 509-515.
17. Wada T et al. Role of angiotensin II in cerebrovascular and renal damages in DOCA/salt hypertensive rats. J Hypertens 1995; 13: 113-122.
18. Kim S et al. Role of angiotensin II in renal injury of deoxycorticosterone acetate-salt hypertensive rats. Hypertension 1994; 24: 195-204.
19. Shibouta Y et al. TCV-116 inhibits renal interstitial and glomerular injury in glomerulosclerotic rats. Kidney Intern 1996; 49 (Suppl 55): S115-S118.
20. Kondo T et al. Disposition of the new angiotensin II receptor antagonist candesartan cilexetil in rats and dogs. Arzneim-Forsch/Drug Res 1996; 46: 594-600.
21. Kondo T et al. Metabolic fate of TCV-116, a new angiotensin II receptor antagonist, in rats and dogs. Jpn Pharmacol Ther 1996; 24 (Suppl 6): 166-167 (English abstract).
22. Kondo T et al. Characterization of conjugated metabolites of a new angiotensin II receptor antagonist, candesartan cilexetil, in rats by liquid chromatography/electrospray tandem mass spectrometry following chemical derivatization. J Mass Spectrom 1996; 31: 873-878.
23. Imai R et al. Preclinical studies of a novel angiotensin II receptor antagonist, TCV-116. Jpn Pharmacol Ther 1996; 24 (Suppl 6): 5-137 (English abstract).
24. Matsuura T et al. Perinatal and postnatal study of trandolapril (RU-44570) in rats. J Toxicol Sci 1993; 18: 133-159 (English abstract).
25. Friberg P et al. Renin-angiotensin system in neonatal rats: inhibition of a renal abnormality in response to ACE inhibition or angiotensin II antagonism. Kidney Intern 1994; 45: 485-492.
26. Kito G, Morimoto S, Shiomi M. General pharmacological properties of the new angiotensin II receptor antagonist (±)-1-cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyf]-1H-benzimidazole- 7-carboxylate. Arzneimittel-Forschung 1996; 46: 1-8.
27. Inada Y et al. Effects of blockades of renin angiotensin system on citric acid-induced cough and capsaicin- or bradykinin-induced plasma extravasation in guinea pigs: comparison of angiotensin converting enzyme inhibitor, enalapril, and angiotensin II receptor antagaonist, candesartan cilexetil (TCV-116). Jpn Pharmacol Ther 1996; 24: 1425-1432.
28. Inada Y et al. Antihypertensive action of a new angiotensin converting enzyme inhibitor, CV-5975, in various hypertensive models. Jpn J Pharmacol 1988; 47: 311-322.
29. Okunishi H, Miyazaki M, Toda N. Evidence for a putatively new angiotensin II-generating enzyme in the vascular wall. J Hypertens 1984; 2: 277-284.
30. Dzau VJ. Significance of the vascular renin-angiotensin pathway. Hypertension 1986; 8: 553-559.
31. Urata H et al. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990; 265: 22348-22357.
32. Leita R, Salgado MCO. Increased vascular formation of angiotensin II in one-kidney, one clip hypertension. Hypertension 1992; 19: 575-581.
33. Tonnesen MG et al. Identification of a human neutrophil angiotensin II-generating protease as cathepsin G. J Clin Invest 1982; 69: 25-30.
34. Boucher R et al. Tonin, angiotensin II system: a review. Circ Res 1977; 41: 11-26.
35. Arakawa K, Maruta H. Ability of kallikrein to generate angiotensin II-like pressor substance and a proposed kinin-tensin enzyme system. Nature 1980; 288: 705-706.